

NDA 206947/S-013

SUPPLEMENT APPROVAL

Eisai Inc. Attention: Jin Cho Associate Director, Global Regulatory Strategy 155 Tice Boulevard Woodcliff Lake, NJ 07677

Dear Ms. Cho:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 30, 2019, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lenvima (lenvatinib) Capsules.

This "Changes Being Effected" supplemental new drug application provides for the revision of blister card container labels and carton labeling to prominently display the specific daily dosing instructions on the principal display panel (PDP) to minimize wrong dose errors.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to enclosed carton and immediate container labels and carton and immediate container labels submitted on October 30, 2019, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3).* For administrative purposes, designate this submission "Product Correspondence – Final Printed Carton and Container Labels for approved NDA 206947/S-013." Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

U.S. Food & Drug Administration Silver Spring, MD 20993 www.fda.gov If you have any questions, call Jessica Springer, Regulatory Business Process Manager, at (240) 402 - 5926.


Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D. Chief, Branch I Division of Post-Marketing Activities I Office of Lifecycle Drug Products Office of Pharmaceutical Quality Center for Drug Evaluation and Research

Enclosure:

Carton and Container Labeling



Digitally signed by Ramesh Raghavachari Date: 4/23/2020 02:05:02PM GUID: 502d0913000029f375128b0de8c50020